Navigation Links
Bloomberg BNA Publishes Sixth Edition of False Claims Act Treatise
Date:3/1/2013

ARLINGTON, Va., March 1, 2013 /PRNewswire-USNewswire/ -- Bloomberg BNA has published the Sixth Edition of False Claims Act: Whistleblower Litigation, providing guidance and analysis of the False Claims Act (FCA) and the many different legislative developments and judicial opinions surrounding it, including qui tam cases in which a private citizen assists in a government prosecution and is paid a percentage of the recovery. Written by the trial lawyer called to testify before Congress on ways to modernize, update, and streamline the FCA, this treatise offers authoritative insights from one of the country's most experienced FCA lawyers.

(Logo: http://photos.prnewswire.com/prnh/20120110/DC33627LOGO)  

In False Claims Act: Whistleblower Litigation, Sixth Edition, practitioners will find discussion of:

  • Pharmaceutical company liability
  • Circuit-by-circuit analysis of Civil Rule 9(b) to FCA complaints
  • Bankruptcy proceedings
  • Statute of limitations for whistleblower employment protections
  • Identifying alternate proceedings
  • Disclosure of defendants' fee information
  • Settlement challenges by realtors, non-settling defendants, and the government
  • State and municipal FCA statutes

Since publication of the Fifth Edition in 2007 by Top Gun Publishing LLC (Cincinnati, Ohio), Congress has amended the FCA three times and the courts have issued more than 2,000 opinions related to the Act. These amendments are fully examined and explained in the Sixth Edition, as are the sometimes conflicting court opinions that have resulted in procedural minefields and other obstacles to proving liability. The Sixth Edition also includes a chapter that details all U.S. Supreme Court opinions related to the Act; a chapter on the numerous state FCAs that have been enacted; and a comprehensive, searchable collection of appendices that provide more than 40 letters, complaints, statements, interrogatories, requests, motions, and affidavits.

With the Sixth Edition, practitioners have all the model forms and procedures needed to effectively litigate qui tam cases. The treatise also includes a table of cases and all versions of this statute and its legislative history, providing a quick reference for both plaintiff and defense attorneys. The Sixth Edition also provides samples of motions in limine used in recent cases; HIPAA and PHSA complaint protective orders; United States Bankruptcy Court Proof of Claim and Application of Trustee to Employ Special Counsel; attorneys' fees and costs application, declaration of counsel, and affidavit in support of an expert; and jury instructions, special interrogatories, and verdict form.

False Claims Act: Whistleblower Litigation, Sixth Edition is authored by James B. Helmer, Jr. , a Senior Partner and President of Helmer, Martins, Rice & Popham Co., L.P.A., in Cincinnati, Ohio. The previous edition was published by Top Gun Publishing LLC (Cincinnati, Ohio). This treatise is available for sale directly from Bloomberg BNA and also will be available on the Bloomberg Law legal research system.

Bloomberg BNA, a wholly owned subsidiary of Bloomberg, is a leading source of legal, regulatory, and business information for professionals. In addition to False Claims Act: Whistleblower Litigation, Bloomberg BNA publishes: Director and Officer Liability in Financial Institutions: A Deskbook; Criminal Tax, Money Laundering, and Bank Secrecy Act Litigation; Whistleblowing: The Law of Retaliatory Discharge; and other titles in litigation. Visit us online for a free catalog, call 1.800.960.1220, or send an email request to books@bna.com.

False Claims Act: Whistleblower Litigation may be purchased (1,594 pp. Hardcover, Order #2197-PR12/$395.00 plus tax, shipping, and handling) from Bloomberg BNA, Book Division, PO Box 7814, Edison, NJ 08818-7814. Telephone orders: 1.800.960.1220. Fax orders: 1.732.346.1624. A 10% discount is available on print copies of books when ordering from the website at www.bna.com/bnabooks. Please note that discounts cannot be combined.

Editors: Review copy available upon request.
Please email Anna Bailey at abailey@bna.com, or call 703.341.5767
Follow us on Twitter @BloombergBNA and @annaebailey6


'/>"/>
SOURCE Bloomberg BNA
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New York City Mayor Bloomberg and Health Commissioner Farley Receive Flu Shot at Duane Reade Pharmacy, Highlight Importance of Flu Preparedness
2. HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
3. Obesity journal publishes new study on lorcaserin, a weight-loss medication recommended for approval by FDA advisory panel
4. Epilepsia Publishes Results From Two Studies Of Eisais Perampanel
5. Pharmspective Publishes New Assessment of Impact of State Exchanges on Key Insurers and Pharma
6. American Journal of Obstetrics and Gynecology Publishes PeriGen Research on Shoulder Dystocia
7. American Journal of Medicine Publishes Hypertension Study Comparing the Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone versus Azilsartan Medoxomil Co-administered with Hydrochlorothiazide
8. Varian Medical Systems Publishes 2012 Sustainability Report Outlining Environmental, Charitable, Safety and Health Access Achievements
9. Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
10. Express Scripts Publishes Inaugural Drug Trend Quarterly, Provides First Comprehensive Overview of U.S. Prescription Drug Spending for 2012
11. Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillions Ovarian Cancer Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/26/2016)... PLAINSBORO, N.J. (PRWEB) , ... June 27, 2016 , ... ... same sources, yet in many ways they remain in the eye of the beholder, ... Oncology (EBO), a publication of The American Journal of Managed Care. For the full ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
Breaking Medicine News(10 mins):